Tag Archives: Vonvendi

December, 2016

5 December
Shire’s Vonvendi Succeeds in Late-Stage Study in Patients with Von Willebrand Disease

Lexington, Mass. – December 2, 2016 – Shire plc (LSE: SHP, NASDAQ: SHPG), the leading biotechnology company focused on serving individuals with rare diseases and other highly specialized conditions, today announced topline results from a Phase 3 clinical trial of VONVENDITM [von Willebrand factor (Recombinant)] to treat bleeds in elective …
Share

8 December
Baxalta Wins FDA Approval for Vonvendi for Treatment of Patients with Von Willebrand Disease

BANNOCKBURN, Ill.–(BUSINESS WIRE)– Baxalta Incorporated (NYSE: BXLT), a global biopharmaceutical leader dedicated to delivering transformative therapies to patients with orphan diseases and underserved conditions, announced today that the U.S. Food and Drug Administration (FDA) has approved VONVENDI [von Willebrand factor (Recombinant)]. VONVENDI is the first and only recombinant treatment for …
Share